Clinical utility of serum macrophage migration inhibitory factor in men with prostate cancer as a novel biomarker of detection and disease progression

Oncology Reports

Volumn 15, Issue 1, 2006, Pages 253-257

  Muramaki, Mototsugu ^a   Miyake, Hideaki ^b   Yamada, Yuji ^a   Hara, Isao ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

Author keywords

Macrophage migration inhibitory factor; Prostate cancer; PSA; Systematic biopsy

Indexed keywords

MACROPHAGE MIGRATION INHIBITION FACTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD; DISEASE COURSE; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33644874077     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.1.253     Document Type: Article

References (27)

1. Denis L and Murphy GP: Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 72: 3888-3895, 1993. (Pubitemid 23361549)
2. Oesterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907-923, 1991.
3. Polascik TJ, Oesterling JE and Partin AW: Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol 162: 293-306, 1999. (Pubitemid 29434327)
4. Catalona WJ, Smith DS, Ratliff TL and Basler JW: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270: 948-954, 1993. (Pubitemid 23244733)
5. Ravery V, Boccon-Gibod LA, Dauge-Geffroy MC, et al: Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. Urology 44: 371-376, 1994. (Pubitemid 24273820)
6. Culig Z, Bartsch G and Hobisch A: Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol Cell Endocrinol 197: 231-238, 2002. (Pubitemid 35304797)
7. Grossmann ME, Huang H and Tindall DJ: Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93: 1687-1697, 2001. (Pubitemid 33130257)
8. Bacher M, Schrader J, Thompson N, et al : Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme. Am J Pathol 162: 11-17, 2003. (Pubitemid 36041985)
9. Ren Y, Tsui HT, Poon RT, et al: Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer 107: 22-29, 2003. (Pubitemid 37100081)
10. White ES, Flaherty KR, Carskadon S, et al : Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res 9: 853-860, 2003. (Pubitemid 36182624)
11. Bando H, Matsumoto G, Bando M, et al: Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread. Jpn J Cancer Res 93: 389-396, 2002. (Pubitemid 34506248)
12. Meyer-Siegler K: Increased stability of macrophage migration inhibitory factor (MIF) in DU-145 prostate cancer cells. J Interferon Cytokine Res 20: 769-778, 2000.
13. Karan D, Kelly DL, Rizzino A, Lin MF and Batra SK: Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis 23: 967-975, 2002. (Pubitemid 34752952)
14. David JR: Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 56: 72-77, 1966.
15. Bloom BR and Bennett B: Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153: 80-82, 1966.
16. Bucala R: MIF re-discovered: pituitary hormone and glucocorticoid-induced regulator of cytokine production. Cytokine Growth Factor Rev 7: 19-24, 1996.
17. Nishihira J, Ishibashi T, Fukushima T, Sun B, Sato Y and Todo S: Macrophage migration inhibitory factor (MIF): Its potential role in tumor growth and tumor-associated angiogenesis. Ann NY Acad Sci 995: 171-182, 2003. (Pubitemid 36706624)
18. Arcuri F, del Vecchio MT, de Santi MM, et al: Macrophage migration inhibitory factor in the human prostate: identification and immunocytochemical localization. Prostate 39: 159-165, 1999. (Pubitemid 29203402)
19. Meyer-Siegler K and Hudson PB: Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology 48: 448-452, 1996. (Pubitemid 26317487)
20. Del Vecchio MT, Tripodi SA, Arcuri F, et al : Macrophage migration inhibitory factor in prostatic adenocarcinoma: correlation with tumor grading and combination endocrine treatment-related changes. Prostate 45: 51-57, 2000.
21. Meyer-Siegler KL, Bellino MA and Tannenbaum M: Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer 94: 1449-1456, 2002. (Pubitemid 34212639)
22. Michael A, Stephan C, Kristiansen G, et al: Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation. Prostate 62: 34-39, 2005. (Pubitemid 39614291)
23. International Union Against Cancer: TNM Classification of Malignant Tumors. Sobin LH and Wittekind CH (eds). New York, John Wiley & Sons, pp170-173, 1997.
24. Sun B, Nishihira J, Yoshiki T, et al: Macrophage migration inhibitory factor promotes tumor invasion and metastasis via the rho-dependent pathway. Clin Cancer Res 11: 1050-1058, 2005. (Pubitemid 40175753)
25. Khan N, Cromer CJ, Campa M and Patz EF Jr: Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of non-small cell lung carcinoma. Cancer 101: 379-384, 2004. (Pubitemid 38890843)
26. Tsuzuki T, Hernandez DJ, Aydin H, Trock B, Walsh PC and Epstein JI: Prediction of extraprostatic extension in the neurovascular bundle based on prostate needle biopsy pathology, serum prostate specific antigen and digital rectal examination. J Urol 173: 450-453, 2005.
27. Partin AW, Yoo J, Carter HB, et al: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150: 110-114, 1993. (Pubitemid 23175983)